AZN vs. WAT: AstraZeneca vs. Waters Stock Comparison

November 11, 2026

How do AstraZeneca (AZN) and Waters (WAT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AstraZeneca (AZN) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while WAT is classified in Life Sciences Tools & Services.

Waters (WAT) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for AstraZeneca (AZN) and Waters (WAT)
Profile Item	AZN	WAT
Name	AstraZeneca PLC American Depositary Shares	Waters Corporation
Country/Region	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	289.14 billion USD	44.93 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	May 12, 1993	November 17, 1995
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

AZN

WAT

GSPC

AstraZeneca (AZN) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AstraZeneca (AZN) and Waters (WAT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AstraZeneca (AZN) and Waters (WAT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
Total Return (1Y)	12.64%	27.70%
Total Return (3Y, Annualized)	15.75%	23.32%
Total Return (5Y, Annualized)	10.63%	6.27%

Risk Profile

Drawdown History

AZN

WAT

GSPC

AstraZeneca (AZN) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AstraZeneca (AZN) and Waters (WAT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
Volatility (1Y, Annualized)	28.21%	35.45%
Beta (5Y)	0.22	1.13
Max Drawdown (5Y)	-27.87%	-36.47%
Avg. Volume (3M)	3.14M	816.72K

Risk-Adjusted Performance

Risk-Return Positioning

AZN and WAT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
Sharpe Ratio (1Y)	0.30	0.66
Sortino Ratio (1Y)	0.44	0.98

Profitability

ROE (TTM)

AstraZeneca (AZN) at 22.57% sits in the top ROE quartile, while Waters (WAT) at 1.12% is closer to the peer norm — stronger capital efficiency for AZN.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.57%

Max: 109.18%
AZN: 22.57%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12%

Max: 109.18%
Q3: 6.23%
WAT: 1.12%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

AstraZeneca (AZN) at 17.68% retains a top-quartile share of revenue as profit, ahead of Waters (WAT) at 1.76%, which keeps about the industry-typical share.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.68%

Max: 18.05%
AZN: 17.68%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.76%

Max: 18.05%
Q3: 4.78%
WAT: 1.76%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AstraZeneca (AZN) at 29.57% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.57%

Max: 83.12%
AZN: 29.57%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.38%

Max: 83.12%
Q3: 14.77%
WAT: 11.38%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
ROE (TTM)	22.57%	1.12%
ROA (TTM)	8.59%	2.36%
Net Margin (TTM)	17.68%	1.76%
Operating Margin (TTM)	29.57%	11.38%
Gross Margin (TTM)	81.78%	49.83%

Growth

Revenue Growth

Both AstraZeneca (AZN) at 8.63% and Waters (WAT) at 6.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AstraZeneca (AZN) at 45.33% and Waters (WAT) at 0.47% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
Revenue Growth (YoY)	8.63%	6.99%
Revenue Growth (3Y CAGR)	9.82%	2.12%
EPS Growth (YoY)	45.33%	0.47%
EPS Growth (3Y CAGR)	45.80%	-2.84%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: AstraZeneca (AZN) shows current ratio of 1.01 against its industry benchmark, while Waters (WAT) has no reading this period.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AZN: 1.01
Min: 0.10

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
WAT: --

AstraZeneca (AZN) vs. Waters (WAT): WAT does not report current ratio, so it has no value marker; AZN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

Waters (WAT) at 0.34 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.66

Max: 1.42
AZN: 0.66
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.34

Max: 1.42
Q3: 0.65
WAT: 0.34
Median: 0.15
Q1: 0.02
Min: 0.00

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
Current Ratio (MRQ)	1.01	--
Debt / Equity (MRQ)	0.66	0.34
Net Debt / EBITDA	1.23	3.23

Dividends

Dividend Yield (TTM)

Waters (WAT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73%

AZN: 1.73%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Waters (WAT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.38%

AZN: 45.38%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
Dividend Yield (TTM)	1.73%	0.00%
Dividend Payout Ratio (TTM)	45.38%	0.00%

Valuation

P/E Ratio (TTM)

AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while Waters (WAT) at 191.46 sits above its peer range — an unusually expensive price for WAT’s trailing earnings.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.37

Max: 85.34
Q3: 43.46
Median: 26.69
AZN: 26.37
Q1: 13.30
Min: 0.07

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

191.46

WAT: 191.46
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AstraZeneca (AZN) at 4.63 and Waters (WAT) at 8.01 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.63

Max: 58.18
Q3: 25.77
Median: 7.30
AZN: 4.63
Q1: 3.01
Min: 0.01

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.01

Max: 58.18
Q3: 25.77
WAT: 8.01
Median: 7.30
Q1: 3.01
Min: 0.01

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both AstraZeneca (AZN) at 5.59 and Waters (WAT) at 2.94 are valued close to their industries’ norm against book — neither stands out from peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.59

Max: 13.53
Q3: 6.54
AZN: 5.59
Median: 3.25
Q1: 1.69
Min: -5.59

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94

Max: 13.53
Q3: 6.54
Median: 3.25
WAT: 2.94
Q1: 1.69
Min: -5.59

AstraZeneca (AZN) vs. Waters (WAT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AstraZeneca (AZN) and Waters (WAT)
Metric	AZN	WAT
P/E Ratio (TTM)	26.37	191.46
P/S Ratio (TTM)	4.63	8.01
P/B Ratio (MRQ)	5.59	2.94
Free Cash Flow Yield (TTM)	1.95%	--